# The Trump administration’s moves on marijuana and psychedelics signal the start of a new … > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/the-trump-administrations-moves-on-marijuana-and-psychedelics-signal-the-start-of-a-new/ > **Published:** 2026-05-12T09:57:14-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T17:00:44-04:00 > **Clinical Summary:** Federal cannabis policy shifts signal new clinical landscape. What changes for physicians, research access, and patient care in 2025. --- ✦ New CED Clinical Relevance #55 [Clinical Context](https://cedclinic.com/cannabis-hyperemesis-syndrome-treatment-insights-2026/) Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. PolicyResearchMental Health Dr. Caplan’s Take “What we’re seeing is a genuine shift in how federal policy can accommodate [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/), and after two decades of prescribing cannabis while navigating the disconnect between state and federal law, I can tell you this matters immensely for patients who’ve been forced to choose between federal prohibition and their own medical needs.” Clinical Perspective Recent shifts in federal drug policy regarding cannabis and psychedelics reflect changing political attitudes that may accelerate research opportunities and alter the regulatory landscape for these substances in clinical contexts. While increased research access could help clarify therapeutic potential for conditions like [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/), PTSD, and treatment-resistant depression, clinicians should remain cautious about interpreting policy changes as scientific endorsements, as political momentum often outpaces rigorous evidence generation. The complexity is compounded by persistent state-federal legal tensions, variable product quality and potency in unregulated markets, and gaps in our understanding of long-term safety profiles and optimal dosing across populations. As these substances potentially become more accessible to patients, healthcare providers should stay informed about emerging evidence, maintain awareness of their own state’s regulations, and engage in shared decision-making conversations that clearly distinguish between preliminary research promise and established clinical efficacy. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20The%20Trump%20administration%27s%20moves%20on%20marijuana%20and%20psychedelics%20signal%20the%20start%20of%20a%20new%20...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D52352)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D52352)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20The%20Trump%20administration%27s%20moves%20on%20marijuana%20and%20psychedelics%20signal%20the%20start%20of%20a%20new%20...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D52352)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [White House Advances Psychedelic Research for Veterans—Why Cannabis Could Benefit Next](https://cedclinic.com/2026-cannabis-psychedelic-research-veterans/) - [CED Digest: 239 Items — March 17, 2026](https://cedclinic.com/cannabis-clinical-digest-march-17-2026/) - [CED Digest: 436 Items — March 14, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) 📰 Source: [https://www.facebook.com/WATE6OnYourSide/posts/the-trump-administrations-moves-on-marijuana-and-psychedelics-signal-the-start-o/1421561393342511/](https://www.facebook.com/WATE6OnYourSide/posts/the-trump-administrations-moves-on-marijuana-and-psychedelics-signal-the-start-o/1421561393342511/) Further Reading CED Clinic Blog[When Ketogenic Diet Therapy Is Added After CBD](https://cedclinic.com/cbd-ketogenic-diet-epilepsy/) Research Digest[Research Digest: 20 Recent Studies – May 02, 2026](https://cedclinic.com/cannabinoid-based-interventions-autism-safety-effectiveness-2026/) Cannabis Policy Wire[Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I](https://cedclinic.com/mdmb-4en-pinaca-schedule-i-placement/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).